The combination of calreticulin-targeting L-ASNase and anti-PD-L1 antibody modulates the tumor immune microenvironment to synergistically enhance the antitumor efficacy of radiotherapy
Ying ZhangCurrent affiliation: State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, ChinaV. AkhilInstitute for Molecular Imaging and Theranostics, Department of Nuclear Medicine, Chonnam National University Medical School and Hwasun Hospital, Jeollanam-do, Republic of KoreaHo Seong SeoResearch Division for Radiation Science, Korea Atomic Energy Research Institute, Jeollabuk-do, Republic of KoreaHae‐Ran ParkResearch Division for Radiation Science, Korea Atomic Energy Research Institute, Jeollabuk-do, Republic of KoreaSoo Hyun Kim. Department of Microbiology, Chonnam National University Medical School, Jeollanam-do, Republic of KoreaSung-Hwan You. Institute for Molecular Imaging and Theranostics, Department of Nuclear Medicine, Chonnam National University Medical School and Hwasun Hospital, Jeollanam-do, Republic of KoreaZhipeng LiuBrain Tumor Research Laboratory, Biomedical Research Institute, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of KoreaSoyoung Kim. CNCure Biotech, Inc., Jeollanam-do, Republic of KoreaRukhsora D. Sultonova. Republican Oncology Research Center Tashkent Region Branch, Tashkent, UzbekistanJung‐Joon MinCNCure Biotech, Inc., Jeollanam-do, Republic of KoreaYeongjin HongCNCure Biotech, Inc., Jeollanam-do, Republic of Korea
Ochiq kirishOltin
Litsenziya: cc-by
ABI
Annotatsiya
CRT-specific L-ASNases are useful as additive drug candidates in tumors treated with RT, and combination treatment with anti-PD-L1 antibody increases their therapeutic efficacy.
Hali tarjima qilinmagan
Mavzular
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos69 ta foydalanilgan manba